PROM1 and hepatocellular carcinoma: Chimeric antigen receptor-specific T (CAR-T) cells specifically targeting CD133-positive CSCs have emerged as a promising treatment modality for advanced HCC, offering potential advancements in the therapeutic landscape for this challenging disease.